Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024
SHELTON, Conn., Jan. 3, 2024...

Related Keywords

Canada ,Dublin ,Ireland ,United States ,Ottawa ,Ontario ,Merck Sharpe Dohme ,Jonathan Nugent ,David Rosen ,Lewish Bender ,Bristol Myers Squibb ,Christian Frederick Meyer ,Company Nasdaq ,Ottawa Hospital Research Institute ,Office Of Orphan Products Development ,Drug Administration ,Prnewswire Intensity Therapeutics Inc ,Ontario Institute Of Cancer Research ,Companya Study May ,Intensity Therapeutics Inc ,Investigational New Drug ,New Drug Application ,Study May Proceed ,Chief Executive Officer ,Connective Tissue Oncology ,Assistant Professor ,Sidney Kimmel Cancer Center ,Johns Hopkins University ,Orphan Products Development ,Merck Sharpe ,Ontario Institute ,Cancer Research ,Relations Contact ,Royal Marsden Hospital Index ,Markets ,